Holen Sie sich die Stockscreener-App
115.62
2.51%
-2.99
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$118.61
Offen:
$117.97
24-Stunden-Volumen:
577.07K
Relative Volume:
0.37
Marktkapitalisierung:
$17.28B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
10.44
EPS:
11.07
Netto-Cashflow:
$1.77B
1W Leistung:
-3.04%
1M Leistung:
-17.93%
6M Leistung:
-37.38%
1J Leistung:
-40.51%
1-Tages-Spanne:
$115.44
$118.61
1-Wochen-Bereich:
$114.66
$119.93
52-Wochen-Spanne:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
115.62 | 17.28B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
808.96 | 754.43B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
155.80 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
168.77 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.11 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.16 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Earnings Preview: What To Expect From Biogen's Report - TradingView
Bleeding Disorders Treatment Market Set to Witness Significant - openPR.com
Biogen (NASDAQ:BIIB) shareholders have endured a 61% loss from investing in the stock five years ago - simplywall.st
Canada Pension Plan Investment Board Purchases 56,132 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 141,968 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
PEGylated Proteins Market Positioned for Accelerated Growth - openPR.com
Canada Post Corp Registered Pension Plan Acquires Shares of 9,718 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sterling Capital Management LLC Has $1.32 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leerink Partnrs Has Bearish Estimate for Biogen Q2 Earnings - MarketBeat
Biogen/ Eisai win EU approval for Alzheimer’s therapy - MSN
Jump Financial LLC Grows Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush Has Positive Forecast for Biogen Q2 Earnings - MarketBeat
Wedbush Estimates Biogen's Q1 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Treasurer of the State of North Carolina - MarketBeat
Fmr LLC Acquires 376,356 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wells Fargo & Company MN Has $16.98 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Buys 14,306 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global factor VIII deficiency treatment Market Generated - openPR.com
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - TradingView
Neuberger Berman Group LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Top Development & Construction Projects: Kendall Common – MIT’s Volpe Redevelopment & Biogen’s New Global HQ - Boston Real Estate Times
BMO Capital Adjusts Biogen Price Target to $128 From $139 - marketscreener.com
Phoenix Financial Ltd. Acquires New Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FIL Ltd Sells 91,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
European regulators OK Alzheimer's treatment Leqembi after initial doubts - Chron
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment - Reuters
LPL Financial LLC Sells 20,253 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - Yahoo Finance
European regulators OK Alzheimer’s treatment Leqembi after initial doubts - AP News
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s - Yahoo Finance
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday - marketscreener.com
Wedbush Cuts Biogen Price Target to $121 From $135, Maintains Neutral Rating - MarketScreener
Causeway Capital Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Genentech Set for June Trial Over MS Drug Royalties - USA Herald
Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU - MarketScreener
Bank of Montreal Can Sells 8,575 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
APG Asset Management US Inc. Buys New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease - geneonline.com
FY2025 EPS Estimates for Biogen Cut by Cantor Fitzgerald - MarketBeat
Biogen, Genentech Head To June Trial Over MS Drug Royalties - Law360
APG Asset Management N.V. Has $15.57 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
First Foundation Advisors Raises Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval - marketscreener.com
Leqembi®∇ (lecanemab) is the First Medicine that Slows - GlobeNewswire
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union - Biogen
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light - Stock Titan
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):